Dulaglutide (Trulicity)
GLP-1 agonist · GLP-1 class · sc weekly · Eli Lilly
Top dose
4.5 mg
HbA1c reduction
-1.77%
at week 36 · efficacy
AE discontinuation
6.0%
Status
approved
Pivotal trial
- Trial
- AWARD-11
- Indication
- type 2 diabetes
- Duration
- 36 weeks
- ClinicalTrials.gov
- NCT03495102
- Sponsor
- Eli Lilly
Notes
AWARD-11 (Frias 2021): dulaglutide 4.5 mg HbA1c -1.77% vs 1.5 mg -1.54%, baseline 8.6%. Established weekly GLP-1; included as the incumbent benchmark for the next-gen race.